S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)

10x Genomics Stock Price, News & Analysis (NASDAQ:TXG)

$45.33
-0.96 (-2.07%)
(As of 12/5/2023 ET)
Compare
Today's Range
$44.57
$46.04
50-Day Range
$34.32
$46.29
52-Week Range
$31.28
$63.57
Volume
748,925 shs
Average Volume
964,386 shs
Market Capitalization
$5.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.78

10x Genomics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
34.1% Upside
$60.78 Price Target
Short Interest
Healthy
4.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.34mentions of 10x Genomics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.27 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.84) to ($1.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

143rd out of 948 stocks

Analytical Instruments Industry

7th out of 27 stocks


TXG stock logo

About 10x Genomics Stock (NASDAQ:TXG)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

TXG Stock Price History

TXG Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
10x Genomics, Inc. (NASDAQ:TXG) CFO Sells $72,767.86 in Stock
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Reviewing 10x Genomics (NASDAQ:TXG) and Revvity (NYSE:RVTY)
Harvard University Stocks List: Top 12 Picks
Here’s Why You Should Invest in 10x Genomics (TXG)
10x Genomics: Unveiling The Investment Potential
Q3 2023 10X Genomics Inc Earnings Call
10x Genomics Reports Third Quarter 2023 Financial Results
See More Headlines
Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/21/2024

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TXG
Fax
N/A
Employees
1,243
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$60.78
High Stock Price Target
$75.00
Low Stock Price Target
$47.00
Potential Upside/Downside
+34.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-166,000,000.00
Pretax Margin
-36.99%

Debt

Sales & Book Value

Annual Sales
$516.41 million
Book Value
$6.99 per share

Miscellaneous

Free Float
105,620,000
Market Cap
$5.36 billion
Optionable
Optionable
Beta
1.88
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Serge Saxonov Ph.D. (Age 46)
    Co-Founder, CEO & Director
    Comp: $837.68k
  • Dr. Benjamin J. Hindson Ph.D. (Age 48)
    Co-Founder, President, Chief Scientific Officer & Director
    Comp: $615.96k
  • Mr. Justin J. McAnearMr. Justin J. McAnear (Age 47)
    Chief Financial Officer
    Comp: $535.91k
  • Mr. Eric S. Whitaker Esq. (Age 56)
    Chief Legal Officer
    Comp: $558.97k
  • Mr. James L. Wilbur Ph.D. (Age 58)
    Chief Commercial Officer
    Comp: $390.78k
  • Mr. Michael Schnall-Levin
    Founding Scientist & CTO
  • Ms. Cassie Corneau
    Manager of Investor Relations and Strategic Finance
  • Ms. Rebecca Port
    Chief People Officer
  • Mr. James Bryant
    Director of Legal
  • Mr. Nikhil Rao
    Director of Product Management














TXG Stock Analysis - Frequently Asked Questions

Should I buy or sell 10x Genomics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TXG shares.
View TXG analyst ratings
or view top-rated stocks.

What is 10x Genomics' stock price target for 2024?

8 analysts have issued 12 month target prices for 10x Genomics' stock. Their TXG share price targets range from $47.00 to $75.00. On average, they expect the company's share price to reach $60.78 in the next year. This suggests a possible upside of 34.1% from the stock's current price.
View analysts price targets for TXG
or view top-rated stocks among Wall Street analysts.

How have TXG shares performed in 2023?

10x Genomics' stock was trading at $36.44 at the start of the year. Since then, TXG shares have increased by 24.4% and is now trading at $45.33.
View the best growth stocks for 2023 here
.

When is 10x Genomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our TXG earnings forecast
.

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) announced its earnings results on Thursday, November, 2nd. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.45) by $0.06. The company had revenue of $153.64 million for the quarter, compared to analyst estimates of $150.11 million. 10x Genomics had a negative trailing twelve-month return on equity of 24.24% and a negative net margin of 37.79%.

What is Serge Saxonov's approval rating as 10x Genomics' CEO?

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did 10x Genomics IPO?

(TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

Who are 10x Genomics' major shareholders?

10x Genomics' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (10.72%), Baillie Gifford & Co. (7.06%), Morgan Stanley (3.68%), Sands Capital Management LLC (3.37%), ARK Investment Management LLC (2.55%) and Invesco Ltd. (1.88%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, James Wilbur, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Mathai Mammen, Serge Saxonov and Sridhar Kosaraju.
View institutional ownership trends
.

How do I buy shares of 10x Genomics?

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TXG) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -